The European Commission (EC) has approved a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). It is approved in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI), who  have demonstrated disease […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!